

Special Issue

Preoperative Radiotherapy in Cancers

Message from the Guest Editor

Today, preoperative radiotherapy is the standard of care in several tumor entities, as its superiority has been shown in randomized trials in the past. In breast cancer, preoperative radiotherapy has yet to be established.

Applying adjuvant radiotherapy reduces ipsilateral breast recurrences, breast-cancer-specific mortality, and overall mortality significantly. The same advantages can be expected when applying preoperative irradiation. Administering radiotherapy preoperatively would definitely improve the cosmetic outcome in patients undergoing partial mastectomy or mastectomy with immediate reconstruction with autologous flaps. Shrinkage and fibrosis of the flap can be expected to be significantly lower compared with flaps receiving postoperative radiotherapy, as they are not irradiated.

In all cancers, the target volume can be defined more accurately in the preoperative setting than in the postoperative setting after tumor removal.

This Special issue will focus on preoperative radiotherapy in different cancers concerning oncologic endpoints, acute and late side effects, and quality of life.

Guest Editor

Dr. Christiane Matuschek

Department of Radiation Oncology, Heinrich Heine University, 40225 Dusseldorf, Germany

Deadline for manuscript submissions

closed (30 April 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/57334

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)